Table 3.

Altered mimic peptide tolerance of PLP_139–151‐induced EAE

Tol Aga)	No. EAE	Mean group score ± SEM	Mean EAE score ± SEM	Mean day of onset ± SEM
No tol	5/5	3.8 ± 0.2	3.8 ± 0.2	12.0 ± 0.9
OVA	5/5	3.6 ± 0.2	3.6 ± 0.2	11.6 ± 0.8
PLP	2/5	0.4 ± 0.2b)	1.0 ± 0.1b)	14.5 ± 1.5
HI	3/5	0.8 ± 0.4b)	1.3 ± 0.3b)	13.7 ± 1.9
HI–P	5/5	3.0 ± 0.5	3.0 ± 0.5	11.8 ± 0.6
MHV	5/5	3.4 ± 0.2	3.4 ± 0.2	11.8 ± 0.9
MHV+P	5/5	2.0 ± 0.4b)	2.0 ± 0.4b)	11.4 ± 0.4

^a) Separate groups of mice were immunized s.c. on day 0 with 100 µg of PLP_139–151 and were tolerized to OVA_323–339 (OVA), PLP_139–151 (PLP), HI_574–586 (H), HI_574–586–P (H–P), MHV_3821–3832 (MHV), or MHV_3821–3832+P (MHV+P) at 7 days pre and 3 days post immunization with PLP_139–151. Results represent the number of mice that developed EAE, the mean group clinical score ± SEM, the mean EAE score ± SEM (excluding mice not exhibiting disease), and the mean day of onset ± SEM.

^b) p <0.05 compared to control OVA‐tolerized or non‐tolerized mice.